Skip to content

Butanilicaine dihydrogen phosphate

CAS 2081-65-4
40

Safety score · 0–100

Moderate

Derived from EU CosIng regulatory status, PubChem hazard data and published research. How we score.

About

A local anesthetic derivative whose safety profile for cosmetic use is poorly established, with concerns about systemic absorption and sensitizer potential.

Butanilicaine dihydrogen phosphate is a phosphated derivative of butanilicaine, which is a local anesthetic structurally related to procaine and lidocaine. The compound has not undergone safety evaluation under EU Regulation 1223/2009 and is not listed in any EU cosmetics positive list. Local anesthetics in cosmetics raise concerns about unintended pharmacological effects, potential for sensitization, and lack of adequate safety data for repeated dermal exposure.

Known concerns

  • No EU cosmetic safety assessment available
  • Potential for skin sensitization
  • Pharmacological activity concern for dermal absorption
  • Not approved for cosmetic use

References

EU

EU CosIng database

European Commission cosmetic ingredient registry — regulatory status, restrictions, authorised functions.

Check your shelf

Find Butanilicaine dihydrogen phosphate in your products.

Scan any cosmetic product with LuxSense to see if it contains Butanilicaine dihydrogen phosphate and get a full ingredient breakdown with safety scores.

This profile is for educational purposes and does not constitute medical advice. Regulatory status and scientific understanding evolve — always read the physical product label and consult a healthcare professional for personal concerns.